Knight
Highly Engaged Employees
Manufacturing · Canada · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
100 Boul. Alexis-nihon Bureau 600, Montr...Phone Number
(514) 484-4483Website
www.knighttx.comRevenue
$236.3 MillionIndustry
About Knight
Knight Org Chart
Is Knight your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Knight recently announced quarterly report
Check out if Knight is spiking on competitors!
Knight, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Knight
Check if Knight has recently received funding, and reach out quickly before it becomes old news!
Click to see if Knight had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Knight has new funding data
Product Launch: Get notified when Knight launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Knight
Find 3 more new buyers
Company Profile Activity
Activity Insights
Knight is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Knight is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Knight.
Knight Tech Stack
A closer look at the technologies used by Knight
Most Recent Scoops
Knight News & Media
Knight Announces Early Warning Filing Regarding Shares of Crescita
MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. ("Crescita").Knight to Present at the Jefferies 2026 Healthcare Conference in New York City
MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2026 Healthcare Conference on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at www.knighttx.com.Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City
MONTREAL, May 12, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 9:00 am ET at the InterContinental New York Barclay hotel in New York City.
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Knight
Knight Therapeutics Inc., headquartered in Montreal, is a specialty pharmaceutical company focused on acquiring, licensing, marketing, and commercializing innovative prescription medicines across Canada and Latin America. With operations in multiple countries, it delivers a diverse portfolio of pharmaceuticals while building long-term partnerships... Read More